跳至主要内容
临床试验/JPRN-jRCTs051180125
JPRN-jRCTs051180125已完成未知

Effect of Eicosapentaenoic acid/Docosahexaenoic acid on Coronary High-intensity Plaques Detected with Non-contrast T1-Weighted Imaging - The AQUAMARINE EPA/DHA Study

Yasuda Satosi0 个研究点目标入组 84 人开始时间: 2019年3月18日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
84

研究概览

简要总结

The effect of 1-year administration of omega-3 fatty acid (2 doses) on PMR of coronary high risk plaques evaluated by cardiac MRI was not verified compared to no treatment group.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Subjects must meet all of the following criteria.
  • 1.Diagnosed with hyperlipidemia and receiving instructions for lifestyle modification
  • 2.Diagnosed with coronary artery disease and have coronary stenosis exceeding 25%, as measured by computed tomography angiography (CTA) or invasive coronary angiography (CAG).
  • 3.Have been taking an HMG-CoA reductase inhibitor at a fixed dose and administration method from at least 4 weeks before informed consent
  • 4.Have at least one coronary plaque with a plaque to myocardium ratio (PMR) of 1.0 or more in non-contrast T1-weighted cardiac magnetic resonance (CMR) imaging at the screening test
  • 5.Serum LDL-cholesterol level less than 100 mg/dL at the screening test
  • 6.Age less than 20 years at the time of consent
  • 7.Capable of visiting the study centers on an outpatient basis
  • 8.Capable of providing written consent before participation in this study

排除标准

  • 1.Use of EPA preparation within 12 weeks before informed consent
  • 2.Scheduled to undergo percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) during the observation period
  • 3.Presence of type 1 diabetes mellitus or type 2 diabetes mellitus with uncontrolled hyperglycemia (HbA1C more than 8.0%)
  • 4.Clinically apparent impairment of renal function
  • 5.Presence of bleeding (e.g., hemophilia, capillary fragility, gastrointestinal tract ulcer, urinary tract bleeding, hemoptysis, vitreous hemorrhage)
  • 6.History of hypersensitivity to any component of the investigational product
  • 7.Other patients who are inappropriate for participation in this study in the opinion of the principal investigator or investigator.

研究者

发起方
Yasuda Satosi

相似试验